natgillin/translations-raw huggingface dataset:
11 As with all insulins, in elderly patients and patients with hepatic or renal impairment, glucose monitoring should be intensified and dosage adjusted on an individual basis.
Tako kot velja za vse insuline, potrebujejo starejši bolniki in bolniki z okvaro jeter ali ledvic intenzivnejši nadzor glukoze, odmerjanje pa je treba prilagoditi posamezno.
Renal or hepatic impairment may reduce the patient’ s insulin requirements.
Okvara ledvic ali jeter lahko zmanjša bolnikovo potrebo po insulinu.
No studies have been performed with NovoMix 50 in children and adolescents under the age of 18 years.
Z zdravilom NovoMix 50 ni bilo opravljenih raziskav pri otrocih in mladostnikih, mlajših od 18 let.
Administration:
Na in uporabe:
If convenient, the gluteal or deltoid region may be used.
Zdravilo NovoMix 50 se aplicira z injekcijo subkutano v stegno ali trebušno steno. e je prikladno, je mogo e uporabiti glutealni ali deltoidni predel.
Injection sites should be alternated within the same region.
Mesta injiciranj je treba znotraj predela menjati.
As with all types of insulin, the duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.
Tako kot pri vseh vrstah insulina je trajanje delovanja spremenljivo, odvisno od odmerka, mesta injiciranja, krvnega pretoka, temperature in stopnje telesne dejavnosti.
The influence of different injection sites on the absorption of NovoMix 50 has not been investigated.
Vpliv razli nih mest injiciranja na absorpcijo zdravila NovoMix 50 ni raziskan.
NovoMix 50 should never be administered intravenously.
Zdravila NovoMix 50 se nikdar ne sme aplicirati intravensko.
Patients, whose blood glucose control is greatly improved, e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly.
Bolnikom, ki se jim uravnanost glukoze v krvi zelo izboljša, npr. z intenziviranim insulinskim zdravljenjem, se obi ajni opozorilni simptomi hipoglikemije lahko spremenijo in jih je s to možnostjo treba seznaniti.
NovoMix 50 should be administered in immediate relation to a meal.
Zdravilo NovoMix 50 je treba aplicirati neposredno ob obroku.
The rapid onset of action should therefore be considered in patients with concomitant diseases or treatment with other medicinal products where a delayed absorption of food might be expected.
Hiter za etek delovanja je zato treba upoštevati pri bolnikih, pri katerih je mogo e zaradi spremljajo ih bolezni ali zdravljenja z drugimi zdravili pri akovati upo asnjeno absorpcijo hrane.
Changes in strength, brand (manufacturer), type, origin (animal, human, human insulin analogue), and/ or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage.
Zaradi sprememb v jakosti, znamki (izdelovalec), tipu, izvoru (živalski, humani, analog humanega insulina) in/ ali na inu izdelave (tehnologija rekombinantne DNA v primerjavi z insulini živalskega izvora), bo morda treba spremeniti tudi odmerjanje insulina.
If dosage adjustment is needed, it may be done with the first dose or during the first few weeks or months.
Bolniki, ki uporabljajo zdravilo NovoMix 50, utegnejo potrebovati spremembo odmerjanja v primerjavi s svojim obi ajnim insulinom. e je potrebna prilagoditev odmerka, jo je mogo e narediti pri prvem odmerku ali v prvih nekaj tednih ali mesecih.
12 NovoMix 50 contains metacresol, which may cause allergic reactions.
12 Zdravilo NovoMix 50 vsebuje metakrezol, ki lahko povzro i alergijske reakcije.
Beta-blocking agents may mask the symptoms of hypoglycaemia.
Zaviralci beta lahko prikrijejo simptome hipoglikemije.
There is limited clinical experience with NovoMix 50 in pregnancy.
Klini ne izkušnje z zdravilom NovoMix 50 med nose nostjo so omejene.
In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy.
Na splošno sta pri ženskah z diabetesom med celotno nose nostjo in pred na rtovano nose nostjo priporo ljiva intenzivnejša kontrola glukoze v krvi in spremljanje nose nice.
There are no restrictions on treatment with NovoMix 50 during lactation.
Omejitev za zdravljenje z zdravilom NovoMix 50 med dojenjem ni.
However, the NovoMix 50 dosage may need to be adjusted.
Lahko pa je potrebna prilagoditev odmerka zdravila NovoMix 50.
In clinical trials and during marketed use the frequency varies with patient population and dose
V klini nih
During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.
13 preskušanjih ni bilo razlik med celotnim deležem hipoglikemij pri bolnikih, zdravljenih z insulinom aspart, in bolnikih, ki so dobivali humani insulin.
Immune system disorders Uncommon - Urticaria, rash, eruptions
Bolezni imunskega sistema Ob asno – urtikarija, izpuš aj, erupcije
Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.
Zelo redko – anafilakti ne reakcije Med simptomi generalizirane preob utljivosti so lahko generaliziran izpuš aj na koži, srbenje, znojenje, prebavne motnje, angionevroti ni edem, težko dihanje, palpitacije in znižanje krvnega tlaka.
Nervous system disorders Rare - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
Bolezni živ evja Redko – periferna nevropatija Hitro izboljšanje urejenosti glukoze v krvi lahko spremlja motnja, imenovana akutna bole a nevropatija, ki je ponavadi reverzibilna.
Eye disorders Uncommon - Refraction disorder Refraction anomalies may occur upon initiation of insulin therapy.
O esne bolezni Ob asno – refrakcijske motnje Po za etku zdravljenja z insulinom se lahko pojavijo refrakcijske anomalije.
Uncommon - Diabetic retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Ob asno – diabeti na retinopatija Dolgoro no izboljšana urejenost glikemije zmanjša tveganje za napredovanje diabeti ne retinopatije.
Skin and subcutaneous tissue disorders Uncommon - Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Bolezni kože in podkožja Ob asno – lipodistrofija e bolnik mest injiciranj na posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
Uncommon - Local hypersensitivity Local hypersensitivity reactions (redness, swelling and itching at the injection site) may occur during treatment with insulin.
Ob asno – lokalna preob utljivost Med zdravljenjem z insulinom se lahko pojavijo lokalne preob utljivostne reakcije (pordelost, oteklina in srbenje na mestu injiciranja).
General disorders and administration site conditions Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Splošne težave in spremembe na mestu aplikacije Redko – edemi Po za etku zdravljenja z insulinom se lahko pojavijo edemi.
It is therefore recommended that the diabetic patient always carry sugar-containing products • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by
Zato naj ima sladkorni bolnik vedno pri sebi nekaj živil, ki vsebujejo sladkor. • Hude hipoglikemije, ko je bolnik nezavesten, je mogo e zdraviti z glukagonom (0, 5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podu ena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
14 glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person or glucose given intravenously by a medical professional.
Glukozo je treba aplicirati intravensko tudi v primeru, da se bolnik v 10 do 15 minutah ne odzove na glukagon.
Glucose must also be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes.
Ko se bolnik zave, je priporo ljivo, da
Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.
14 peroralno dobi ogljikove hidrate za prepre itev ponovitve.
NovoMix 50 is a biphasic suspension of insulin aspart (rapid-acting human insulin analogue) and protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
Zdravilo NovoMix 50 je dvofazna suspenzija insulina aspart (hitrodelujo ega analoga humanega insulina) in s protaminom kristaliziranega insulina aspart (srednjedolgodelujo ega analoga humanega insulina).
The blood glucose lowering effect of insulin occurs when the molecules facilitate the uptake of glucose by binding to insulin receptors on muscle and fat cells - and simultaneously inhibit the output of glucose from the liver.
U inek insulina na znižanje glukoze v krvi je posledica lažjega privzema glukoze zaradi vezave insulina na insulinske receptorje na miši nih in maš obnih celicah ter hkratne inhibicije sproš anja glukoze iz jeter.
NovoMix 50 is a biphasic insulin, which contains 50% soluble insulin aspart.
Zdravilo NovoMix 50 je dvofazen insulin, ki vsebuje 50% topnega insulina aspart.
The crystalline phase (50%) consists of protamine-crystallised insulin aspart, which has an activity profile that is similar to that of human NPH insulin.
Kristalno fazo (50%) sestavlja s protaminom kristalizirani insulin aspart, ki ima podoben profil aktivnosti kot humani insulin NPH.
When NovoMix 50 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
20
The maximum effect is exerted between 1 and 4 hours after injection.
22
Hours NovoMix 50
Ure NovoMix 50 ----------------------- -------------------
Activity Profile for NovoMix 50 in Healthy Caucasian Subjects.
Profil aktivnosti zdravila NovoMix 50 pri zdravih belcih
15 5.2 Pharmacokinetic properties
15 5. 2 Farmakokineti ne lastnosti
In insulin aspart substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers in the soluble fraction of NovoMix 50, as compared with soluble human insulin.
Substitucija aminokisline prolina z asparaginsko kislino na položaju B28 v insulinu aspart zmanjša nagnjenost k tvorbi heksamerov v topni frakciji zdravila NovoMix 50 v primerjavi s topnim humanim insulinom.
The insulin aspart in the soluble phase of NovoMix 50 comprises 50% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin.
Insulin aspart v topni fazi zdravila NovoMix 50 obsega 50% celotnega insulina; ta se iz podkožja absorbira hitreje kot topna insulinska komponenta dvofaznega humanega insulina.
The remaining 50% is in crystalline form as protamine-crystallised insulin aspart; this has a prolonged absorption profile similar to human NPH insulin.
Preostalih 50% je v kristalni obliki kot insulin aspart, kristaliziran s protaminom, ki ima podaljšan potek absorpcije, podoben humanemu insulinu NPH.
In healthy volunteers a mean maximum serum concentration of 445 ± 135 pmol/ l was reached about 60 minutes after a subcutaneous dose of 0.30 U/ kg body weight.
Pri zdravih prostovoljcih je bila povpre na najve ja koncentracija v serumu 445 ± 135 pmol/ l dosežena okrog 60 minut po subkutanem odmerku 0, 30 e. / kg telesne mase.
In type 2 patients with diabetes, the maximum concentration was reached about 95 minutes after dosing.
Pri bolnikih z diabetesom tipa 2 je bila najve ja koncentracija dosežena približno 95 minut po uporabi.
The pharmacokinetics of NovoMix 50 has not been investigated in elderly, children or patients with impaired renal or liver function.
Farmakokinetika zdravila NovoMix 50 ni raziskana pri starejših osebah, otrocih in bolnikih z okvarjenim delovanjem ledvic ali jeter.
In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin.
V preskusih in vitro, vklju no z vezavo na receptorska mesta za insulin in IGF- 1 ter u inki na celi no rast, se je insulin aspart obnašal zelo podobno humanemu insulinu.
Store in a refrigerator (2°C – 8°C) away from the freezing compartment.
Shranjujte v hladilniku pri temperaturi med 2 °C in 8 °C, ne blizu zamrzovalnega razdelka.
16 NovoMix 50 Penfill cartridges in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
16 Injekcijski vložki NovoMix 50 Penfill, ki so v uporabi ali jih ima bolnik pri sebi za rezervo: do 4 tedne, jih je mogo e hraniti na sobni temperaturi (do 30 °C), toda ostanek je treba po tem asu zavre i.
Keep the cartridges in the outer carton in order to protect from light.
Injekcijske vložke shranjujte v zunanji ovojnini za zagotovitev zaš ite pred svetlobo.
After removing NovoMix 50 Penfill from the refrigerator it is recommended to allow NovoMix 50 Penfill to reach room temperature before resuspending the insulin as instructed for the first time use.
Potem ko zdravilo NovoMix 50 Penfill vzamete iz hladilnika, ga je priporo ljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
A glass (Type 1) cartridge which is closed with a latex-free (bromobutyl) rubber piston at one end and a latex-free (bromobutyl/ polyisoprene) rubber closure at the other.
Steklen vložek (steklo tipa 1) je na enem koncu zaprt z batom iz (bromobutilne) gume brez lateksa in na drugi strani z zaporko iz (bromobutilne/ poliizoprenske) gume brez lateksa.
Each cartridge contains 3 ml suspension.
Vsak injekcijski vložek vsebuje 3 ml suspenzije.
Cartons of 1, 5 or 10 cartridges.
Škatle z 1, 5 ali 10 injekcijskimi vložki.
The cartridges are designed to be used with Novo Nordisk delivery systems (durable devices for repeated use) and NovoFine needles.
Injekcijski vložki so namenjeni za uporabo v sistemih za dajanje insulina Novo Nordisk (trajni pripomo ki za ve kratno uporabo) in z iglami NovoFine.
Detailed instruction accompanying the cartridge and delivery system must be followed.
Upoštevati je treba podrobno navodilo, priloženo injekcijskim vložkom in aplikacijskemu sistemu.
NovoMix 50 Penfill is for use by one person only.
Vložek NovoMix 50 Penfill je namenjen uporabi ene same osebe.
NovoMix 70 Penfill 100 U/ ml, suspension for injection in a cartridge.
NovoMix 70 Penfill 100 e. / ml suspenzija za injiciranje v injekcijskem vložku
Soluble insulin aspart*/ protamine-crystallised insulin aspart*…… ..100 U/ ml in the ratio of 70/ 30
Topni insulin aspart * / s protaminom kristalizirani insulin aspart *......... 100 e. / ml v razmerju 70/ 30
Suspension for injection in a cartridge.
Suspenzija za injiciranje v napolnjenem injekcijskem peresniku.
NovoMix 70 is a white suspension.
Zdravilo NovoMix 70 je bela suspenzija.
When necessary, NovoMix 70 can be given soon after start of a meal.
Hiter za etek delovanja in zgoden vrh delovanja insulina aspart omogo ata uporabo zdravila NovoMix 70 tik pred obrokom. e je potrebno, je mogo e zdravilo NovoMix 70 dati kmalu po za etku obroka.
Dosage of NovoMix 70 is individual and determined on the basis of the physician’ s advice in accordance with the patient’ s needs.
Odmerjanje zdravila NovoMix 70 je individualno in dolo eno na podlagi zdravnikovega nasveta v skladu z bolnikovimi potrebami.
The individual insulin requirement is usually between 0.5 and 1.0 Units/ kg/ day in adult patients and this may be fully or partially supplied with NovoMix 70.
Individualna potreba po insulinu je pri odraslih bolnikih ponavadi od 0, 5 do 1, 0 enot/ kg/ dan in jo lahko v celoti ali delno pokrije zdravilo NovoMix 70.
In patients with type 2 diabetes, NovoMix 70 can be given in monotherapy or in combination with metformin, when the blood glucose is inadequately controlled with metformin alone.
Pri bolnikih z diabetesom tipa 2 lahko zdravilo NovoMix 70 uporabite v monoterapiji ali v kombinaciji z metforminom, e glukoza v krvi s samim metforminom ni zadostno urejena.
Transfer to NovoMix 70 from other insulin preparations may require adjustment of dose and timing of administration.
Pri prehodu z drugih insulinov na zdravilo NovoMix 70 utegne biti potrebna prilagoditev odmerka in asa uporabe.
18 As with all insulins, in elderly patients and patients with hepatic or renal impairment, glucose monitoring should be intensified and dosage adjusted on an individual basis.
Tako kot velja za vse insuline, potrebujejo starejši bolniki in bolniki z okvaro jeter ali ledvic intenzivnejši nadzor glukoze, odmerjanje pa je treba prilagoditi posamezno.
No studies have been performed with NovoMix 70 in children and adolescents under the age of 18 years.
Z zdravilom NovoMix 70 ni bilo opravljenih raziskav pri otrocih in mladostnikih, mlajših od 18 let.
If convenient, the gluteal or deltoid region may be used.
Zdravilo NovoMix 70 se aplicira z injekcijo subkutano v stegno ali trebušno steno. e je prikladno, je mogo e uporabiti glutealni ali deltoidni predel.
The influence of different injection sites on the absorption of NovoMix 70 has not been investigated.
Vpliv razli nih mest injiciranja na absorpcijo zdravila NovoMix 70 ni raziskan.
NovoMix 70 should never be administered intravenously.
Zdravila NovoMix 70 se nikdar ne sme aplicirati intravensko.
NovoMix 70 should be administered in immediate relation to a meal.
Zdravilo NovoMix 70 je treba aplicirati neposredno ob obroku.
Changes in strength, brand (manufacturer), type, origin (animal, human, human insulin analogue), and/ or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage.
Zaradi sprememb v jakosti, znamki (izdelavi), vrsti, izvoru (živalski, humani, analog humanega insulina) in/ ali na inu izdelave (rekombinantna DNA ali živalski vir insulina), imajo lahko za posledico spremembo odmerjanja.
If dosage adjustment is needed, it may be done with the first dose or during the first few weeks or months.
Bolniki, ki uporabljajo zdravilo NovoMix 70, utegnejo potrebovati spremembo odmerjanja v primerjavi s svojim obi ajnim insulinom. e je potrebna prilagoditev odmerjanja, jo je mogo e narediti pri prvem odmerku ali v prvih nekaj tednih ali mesecih.
19 NovoMix 70 contains metacresol, which may cause allergic reactions.
19 Zdravilo NovoMix 70 vsebuje metakrezol, ki lahko povzro i alergijske reakcije.
There is limited clinical experience with NovoMix 70 in pregnancy.
Klini ne izkušnje z zdravilom NovoMix 70 med nose nostjo so omejene.
There are no restrictions on treatment with NovoMix 70 during lactation.
Omejitev za zdravljenje z zdravilom NovoMix 70 med dojenjem ni.
However, the NovoMix 70 dosage may need to be adjusted.
Lahko pa je potrebna prilagoditev odmerka zdravila NovoMix 70.
In clinical trials and during marketed use the frequency varies with patient population and dose
Pogostnost v klini nih preskušanjih in med uporabo, ko je insulin že na trgu, se spreminja glede na populacijo bolnikov in odmerne sheme, zato natan ne pogostnosti ni mogo e navesti.
20 regimens therefore no specific frequency can be presented.
20 aspart, in bolnikih, ki so dobivali humani insulin.
NovoMix 70 is a biphasic suspension of insulin aspart (rapid-acting human insulin analogue) and protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
Zdravilo NovoMix 70 je dvofazna suspenzija insulina aspart (hitrodelujo ega analoga humanega insulina) in s protaminom kristaliziranega insulina aspart (srednjedolgodelujo ega analoga humanega insulina).
NovoMix 70 is a biphasic insulin, which contains 70% soluble insulin aspart.
Zdravilo NovoMix 70 je dvofazen insulin, ki vsebuje 70% topnega insulina aspart.
The crystalline phase (30%) consists of protamine-crystallised insulin aspart, which has an activity profile that is similar to that of human NPH insulin.
Kristalno fazo (30%) sestavlja s protaminom kristalizirani insulin aspart, ki ima podoben profil aktivnosti kot humani insulin NPH.
When NovoMix 70 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
20
Hours NovoMix 70
Ure NovoMix 70 ----------------------- -------------------
Activity Profile for NovoMix 70 in Healthy Caucasian Subjects.
Profil aktivnosti zdravila NovoMix 70 pri zdravih belcih
22 5.2 Pharmacokinetic properties
22 nagnjenost k tvorbi heksamerov v topni frakciji zdravila NovoMix 70 v primerjavi s topnim humanim insulinom.
The insulin aspart in the soluble phase of NovoMix 70 comprises 70% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin.
Insulin aspart v topni fazi zdravila NovoMix 70 obsega 70% celotnega insulina; ta se iz podkožja absorbira hitreje kot topna insulinska komponenta dvofaznega humanega insulina.
The remaining 30% is in crystalline form as protamine-crystallised insulin aspart; this has a prolonged absorption profile similar to human NPH insulin.
Preostalih 30% je v kristalni obliki kot insulin aspart, kristaliziran s protaminom, ki ima podaljšan potek absorpcije, podoben humanemu insulinu NPH.
In healthy volunteers a mean maximum serum concentration of 645 ± 185 pmol/ l was reached about 60 minutes after a subcutaneous dose of 0.30 U/ kg body weight.
Pri zdravih prostovoljcih je bila povpre na najve ja koncentracija v serumu 645 ± 185 pmol/ l dosežena okrog 60 minut po subkutanem odmerku 0, 30 e. / kg telesne mase.
In type 2 patients with diabetes, the maximum concentration was reached about 75 minutes after dosing.
Pri bolnikih z diabetesom tipa 2 je bila najve ja koncentracija dosežena približno 75 minut po uporabi.
In type 1 patients with diabetes a mean maximum serum concentration of 721 ± 184 pmol/ l was reached about 60 minutes after a subcutaneous dose of 0.30 U/ kg body weight.
Pri bolnikih z diabetesom tipa 1 je bila povpre na najve ja koncentracija v serumu 721 ± 184 pmol/ l dosežena okrog 60 minut po subkutanem odmerku 0, 30 e. / kg telesne mase.
The pharmacokinetics of NovoMix 70 has not been investigated in elderly, children or patients with impaired renal or liver function.
Farmakokinetika zdravila NovoMix 70 ni raziskana pri starejših osebah, otrocih in bolnikih z okvarjenim delovanjem ledvic ali jeter.
23 6.4 Special precautions for storage
6. 4 Posebna navodila za shranjevanje
NovoMix 70 Penfill cartridges in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
Injekcijski vložki NovoMix 70 Penfill, ki so v uporabi ali jih ima bolnik pri sebi za rezervo: do 4
After removing NovoMix 70 Penfill from the refrigerator it is recommended to allow NovoMix 70 Penfill to reach room temperature before resuspending the insulin as instructed for the first time use.
Potem, ko zdravilo NovoMix 70 Penfill vzamete iz hladilnika, ga je priporo ljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
NovoMix 70 Penfill is for use by one person only.
Vložek NovoMix 70 Penfill je namenjen uporabi ene same osebe.
NovoMix 30 FlexPen 100 U/ ml, suspension for injection in a pre-filled pen.
NovoMix 30 FlexPen 100 e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Soluble insulin aspart*/ protamine-crystallised insulin aspart*………… 100 U/ ml in the ratio of 30/ 70
Topni insulin aspart * / s protaminom kristalizirani insulin aspart * ……... 100 e. / ml v razmerju 30/ 70
Patients, whose blood glucose control is greatly improved, e. g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly.
26 zdravljenjem, se obi ajni opozorilni simptomi hipoglikemije lahko spremenijo in jih je s to možnostjo treba seznaniti.
27 Tighter control of glucose levels can increase the potential for hypoglycaemic episodes and therefore require special attention during dose intensification as outlined in section 4.2.
Strožja urejenost koncentracije glukoze lahko pove a možnost hipoglikemije, zato je med pove evanjem odmerka potrebna posebna previdnost, kot je opisano v poglavju 4. 2.